Xerostomia (dry mouth) therapeutics market is projected to grow at a considerable CAGR of 7% during the forecast period (2019-2025). As per the American Dental Association, the rate of prevalence of xerostomia in the general population ranges from 0.9% to 64.8%. Severance of xerostomia leads to a critical impact on the patient’s health and quality life as it causes oral discomfort to the patient. The rise in the prevalence of Sjogren’s syndrome along with an increase in the consumption of medications is a major factor to drive the growth of the global xerostomia therapeutics market. As per the Association, the prevalence of xerostomia is considered 100% in patients with Sjogren’s syndrome or patients who have undergone radiation therapy for head and neck cancer.